Education
About Us
Working with TipRanks
Follow Us
Alector (ALEC)
:ALEC
ALEC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $6.14
Previous CloseN/A
Volume194.31K
Average Volume (3M)1.18M
Market Cap
$303.64M
Enterprise Value-$127.28M
Total Cash (Recent Filing)$307.28M
Total Debt (Recent Filing)$39.48M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Nov 11, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding101,212,326
10 Day Avg. Volume1,061,495
30 Day Avg. Volume1,184,788
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.42
Enterprise Value/Revenue-1.57
Enterprise Value/Gross Profit-4.05
Enterprise Value/Ebitda0.99
Forecast
1Y Price Target
$3.83Price Target Upside27.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityAlector highlighted the commercial opportunity with latozinemab, with ~55K affected individuals in US and ~110K in EU, and as it relates to latozinemab, ~8-17K symptomatic patients in US and EU, based on the FTD Disorders Registry.
Pipeline DiversificationAlector unveiled newly selected ABC platform candidates, including two anti-Aβ antibodies for Alzheimer's and a GCase enzyme replacement therapy targeting Parkinson's, which diversifies their pipeline.
Regulatory ProgressFollowing a recent FDA meeting, regulators requested the company add plasma progranulin as a co-primary endpoint to the study in the U.S. alongside the functional endpoint.
Bears Say
Regulatory ChallengesThe amendment to include plasma PGRN as a co-primary endpoint in the study is viewed positively due to supportive data from the Phase 2 trial and clear human genetics data supporting PGRN's role in disease pathogenesis.
Trial Outcome RisksIf neither endpoint is met in the INFRONT-3 trial, there is an expectation of a sharp reprice to a platform-only valuation, as the FTD franchise de-risks to zero.
Alector News
ALEC FAQ
What was Alector’s price range in the past 12 months?
Alector lowest stock price was $0.87 and its highest was $6.14 in the past 12 months.
What is Alector’s market cap?
Alector’s market cap is $303.64M.
When is Alector’s upcoming earnings report date?
Alector’s upcoming earnings report date is Nov 11, 2025 which is in 40 days.
How were Alector’s earnings last quarter?
Alector released its earnings results on Aug 07, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.461 by $0.161.
Is Alector overvalued?
According to Wall Street analysts Alector’s price is currently Undervalued.
Does Alector pay dividends?
Alector does not currently pay dividends.
What is Alector’s EPS estimate?
Alector’s EPS estimate is -0.4.
How many shares outstanding does Alector have?
Alector has 101,212,326 shares outstanding.
What happened to Alector’s price movement after its last earnings report?
Alector reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.461. Following the earnings report the stock price went up 47.26%.
Which hedge fund is a major shareholder of Alector?
Currently, no hedge funds are holding shares in ALEC
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.83 (27.67% Upside)
$3.83 (27.67% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 9.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $241.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.06%
12-Months-Change
Fundamentals
Return on Equity
-103.98%
Trailing 12-Months
Asset Growth
-37.55%
Trailing 12-Months
Company Description
Alector
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including strong financial health, upcoming trial data, and completion of enrollment for a key program. However, significant challenges remain, such as regulatory hurdles and the complexity of diagnosing and treating FTD. The balance of promising advancements and existing challenges suggests a cautiously optimistic outlook.View all ALEC earnings summariesALEC Stock 12 Month Forecast
Average Price Target
$3.83
▲(27.67% Upside)
Technical Analysis
Coherus Biosciences
―
Enanta Pharmaceuticals
―
XBiotech
―
C4 Therapeutics
―
Instil Bio
―
Ownership Overview
Currently, No data available
---